Aandeel R5W STEM CELL THERAPEUTICS CORP.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren
Inactief instrument

Andere talen Stem Cell Therapeutics Corp. Xetra

Aandelen

R5W

CA8585721001

slotkoers Xetra
Andere beurzen
- EUR - Intraday-grafiek van Stem Cell Therapeutics Corp.
2022 TCR2 Therapeutics benoemt Chief Business and Strategy Officer MT
2021 Pfizer wil meer expertise in immuno-inflammatoire ziekten met de overname van Arena Pharmaceuticals voor $6,7 miljard MT

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
TCR2 Therapeutics Appoints Chief Business and Strategy Officer
Pfizer Deploying Some of Its Covid Cash in Arena Deal -- Analysis
Pfizer Eyes Enhanced Immuno-Inflammatory Disease Expertise With $6.7 Billion Arena Pharmaceuticals Takeover
Pfizer schluckt kalifornische Biotechfirma für 6,7 Mrd Dollar
Pfizer scommette su promettente farmaco Arena con deal da 6,7 mld $
Trillium Therapeutics Inc.(TSX:TRIL) dropped from S&P Global BMI Index
Pfizer : a finalisé l'acquisition de Trillium Therapeutics
Trillium Therapeutics : Pfizer Completes Acquisition of Trillium Therapeutics - Form 8-K
Pfizer Completes $2.22 Billion Trillium Therapeutics Acquisition
TRILLIUM THERAPEUTICS INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
Trillium Therapeutics Inc. Announces Executive Changes
Trillium Therapeutics Inc. Announces Resignation of Jan Skvarka as Chief Executive Officer
Trillium Therapeutics Inc. Announces Cessation of James Parsons as Chief Financial Officer
Pfizer-Trillium Therapeutics $2.26 Billion Deal Secures Canada, US Approval
Trillium Therapeutics Inc.(NasdaqCM:TRIL) dropped from NASDAQ Composite Index
Pfizer Inc. completed the acquisition of remaining 97.8% stake in Trillium Therapeutics Inc. from New Enterprise Associates 16, L.P., a fund managed by New Enterprise Associates, Inc., Avoro Capital Advisors LLC, RA Capital Healthcare Fund, L.P., a fund managed by RA Capital Management, L.P. and others.
TRILLIUM THERAPEUTICS INC. : Other Events (form 8-K)
Trillium: Q3 Earnings Snapshot
TRILLIUM THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Trillium Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers TRIL
  4. Koers R5W
  5. Nieuws Stem Cell Therapeutics Corp.
  6. Andere talen